Neogenomics (NEO) PT Raised to $13 at Jefferies

Jefferies analyst Tycho Peterson raised the price target on Neogenomics (NASDAQ: NEO) to $13.00 (from $7.50) while maintaining a Buy rating.

The analyst comments "NEO posted a modest beat (+2%), underpinned by solid clinical and NGS momentum, which is a constructive pivot following back-to-back misses. FY25 guidance was reaffirmed. Looking to 2026, we see a favorable setup, aided by MRD expansion (sign up for our upcoming MRD call here), the PanTracer LBx rollout, and operational streamlining as key growth levers. Reiterate Buy. "

You May Also Be Interested In

• Jones Trading Starts Alterity Therapeutics (ATHE) at Buy
• Jefferies Downgrades United Spirits Ltd. (UNITDSPR:IN) to Hold
• Cameco Corp. (CCO:CN) (CCJ) PT Raised at RBC Capital as 'Uranium continues to strengthen'